SUPPORTING INFECTIOUS DISEASE RESEARCH

Pseudomonas aeruginosa, Strain MRSN 17849

Catalog No. NR-51587

This reagent is the tangible property of the U.S. Government.

Product Description:

Pseudomonas aeruginosa (P. aeruginosa), strain MRSN 17849 is a human respiratory isolate collected in 2013 as part of a surveillance program in the United States. *P. aeruginosa*, strain MRSN 17849 was deposited as sensitive to amikacin, cefepime, ciprofloxacin, gentamicin, imipenem, levofloxacin, meropenem and tobramycin, with intermediate resistance to aztreonam, ceftazidime and piperacillin/tazobactam.

Lot: 70025080¹

Manufacturing Date: 10JUN2019

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology ²	Report results	Circular, convex, entire, smooth and
colory morphology		green (Figure 1)
Motility (wet mount)	Report results	Motile
VITEK [®] 2 (GN card)	<i>P. aeruginosa</i> (≥ 89%)	P. aeruginosa (97%)
Antibiotic Susceptibility Profile ³		
VITEK [®] (AST-GN81 Card)		
Ampicillin	Report results	Resistant (≥ 32 µg/mL)
Amoxicillin/clavulanic acid	Report results	Resistant (≥ 32 µg/mL)
Piperacillin/tazobactam	Intermediate	Resistant (≥ 128 µg/mL) ⁴
Cefazolin	Report results	Resistant (≥ 64 µg/mL)
Cefoxitin	Report results	Resistant (≥ 64 µg/mL)
Ceftazidime	Intermediate	Resistant (≥ 64 µg/mL) ⁵
Ceftriaxone	Report results	Resistant (≥ 64 µg/mL)
Cefepime	Sensitive	Intermediate (16 µg/mL) ⁶
Meropenem	Sensitive	Sensitive (≤ 0.25 µg/mL)
Amikacin	Sensitive	Sensitive (4 µg/mL)
Gentamicin	Sensitive	Sensitive (2 µg/mL)
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)
Ciprofloxacin	Sensitive	Sensitive (≤ 0.25 µg/mL)
Levofloxacin	Sensitive	Sensitive (≤ 0.12 µg/mL)
Tetracycline	Report results	Resistant (≥ 16 µg/mL)
Nitrofurantoin	Report results	Resistant (≥ 512 µg/mL)
Trimethoprim/sulfamethoxazole	Report results	≥ 160 µg/mL ⁷
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene	≥ 99% sequence identity to	100% sequence identity to
(~ 1430 base pairs)	<i>P. aeruginosa</i> , strain MRSN 17849 (GenBank: RXVK01000120.1)	<i>P. aeruginosa</i> , strain MRSN 17849 (GenBank: RXVK01000120.1)
Purity (post-freeze) ⁸	Growth consistent with expected	Growth consistent with expected
	colony morphology	colony morphology
Viability (post-freeze) ²	Growth	Growth

¹NR-51587 was produced by inoculation of the depositor material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.
²1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar

³Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

⁴*P. aeruginosa*, strain MRSN 17849 was deposited as intermediate to piperacillin/tazobactam, but showed a MIC of \geq 128 µg/mL (interpreted as resistant) for piperacillin/tazobactam during QC testing. Testing was performed in duplicate.

⁵*P. aeruginosa*, strain MRSN 17849 was deposited as intermediate to ceftazidime, but showed a MIC of ≥ 64 µg/mL (interpreted as resistant) for ceftazidime during QC testing. Testing was performed in duplicate.

BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 **b**|**e**|**i** resources

Certificate of Analysis for NR-51587


SUPPORTING INFECTIOUS DISEASE RESEARCH

⁶Susceptibility results for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

⁷Trimethoprim/sulfamethoxazole MIC interpretive standards are not available for *P. aeruginosa*, however most clinical isolates are resistant to trimethoprim/sulfamethoxazole. For more information, please refer to Köhler, T., et al. "Multidrug Efflux in Intrinsic Resistance to Trimethoprim and Sulfamethoxazole in *Pseudomonas aeruginosa*." <u>Antimicrob. Agents Chemother.</u> 40 (1996): 2288-2290. PubMed: 9036831.

⁸Purity of this lot was assessed for 8 days at 37°C in an aerobic atmosphere with and without 5% CO₂ on Tryptic Soy agar.

Figure 1: Colony Morphology



/Heather Couch/ Heather Couch

10 MAR 2020

Program Manager or designee, ATCC Federal Solutions

ATCC[®], on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC[®]'s knowledge.

ATCC[®] is a trademark of the American Type Culture Collection. You are authorized to use this product for research use only. It is not intended for human use.

